Table Graph
      published meta-analysis   sensitivity analysis   studies

fluvoxamine in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsACTIV-6, 2022 1.10 [0.64; 1.91] COVID-OUT (fluvoxamine), 2022 1.17 [0.57; 2.40] 1.13[0.73; 1.74]ACTIV-6, 2022, COVID-OUT (fluvoxamine), 202220%653lownot evaluable death D28detailed resultsTOGETHER, 2021 0.69 [0.37; 1.30] 0.69[0.37; 1.30]TOGETHER, 202110%1,497NAnot evaluable deathsdetailed resultsTOGETHER, 2021 0.80 [0.43; 1.50] 0.80[0.43; 1.50]TOGETHER, 202110%1,472NAnot evaluable deaths (time to event analysis only)detailed resultsTOGETHER, 2021 0.80 [0.43; 1.50] 0.80[0.43; 1.50]TOGETHER, 202110%1,472NAnot evaluable hospitalization or deathdetailed resultsCOVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] TOGETHER, 2021 0.76 [0.57; 1.02] 0.78[0.58; 1.03]COVID-OUT (fluvoxamine), 2022, TOGETHER, 202120%2,150moderatenot evaluable clinical deteriorationdetailed resultsCOVID-OUT (fluvoxamine), 2022 0.94 [0.65; 1.35] Lenze (STOP COVID 1), 2020 0.07 [0.00; 1.26] TOGETHER, 2021 0.64 [0.47; 0.87] 0.72[0.45; 1.16]COVID-OUT (fluvoxamine), 2022, Lenze (STOP COVID 1), 2020, TOGETHER, 2021361%2,299moderatenot evaluable hospitalizationdetailed resultsACTIV-6, 2022 0.45 [0.04; 5.03] COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75] TOGETHER, 2021 0.76 [0.57; 1.02] 0.77[0.58; 1.02]ACTIV-6, 2022, COVID-OUT (fluvoxamine), 2022, TOGETHER, 202130%3,438moderatenot evaluable viral clearance detailed resultsTOGETHER, 2021 0.67 [0.42; 1.06] 0.67[0.42; 1.06]TOGETHER, 202110%428NAnot evaluable viral clearance by day 7detailed resultsTOGETHER, 2021 0.67 [0.42; 1.06] 0.67[0.42; 1.06]TOGETHER, 202110%428NAnot evaluable emergency room observation for > 6 hours or hospitalizationdetailed resultsTOGETHER, 2021 0.64 [0.47; 0.87] 0.64[0.47; 0.87]TOGETHER, 202110%1,497NAnot evaluable recoverydetailed resultsACTIV-6, 2022 0.96 [0.86; 1.07] 0.96[0.86; 1.07]ACTIV-6, 202210%NAnot evaluable AE leading to drug discontinuationdetailed resultsTOGETHER, 2021 1.38 [0.98; 1.95] 1.38[0.98; 1.95]TOGETHER, 202110%1,497NAnot evaluable serious adverse eventsdetailed resultsLenze (STOP COVID 1), 2020 0.17 [0.02; 1.49] 0.17[0.02; 1.49]Lenze (STOP COVID 1), 202010%152NAnot evaluable adverse eventsdetailed resultsLenze (STOP COVID 1), 2020 0.98 [0.40; 2.38] 0.98[0.40; 2.38]Lenze (STOP COVID 1), 202010%152NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2025-03-09 15:51 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 632 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons